Mohammadi S, Eslami S, Jones L, Gorbet M
Drug Deliv Transl Res. 2024; .
PMID: 39636534
DOI: 10.1007/s13346-024-01746-z.
Hannestad J, Smith S, Lam A, Hurt J, Harada N, Kim R
Clin Transl Sci. 2024; 17(11):e70064.
PMID: 39535924
PMC: 11559592.
DOI: 10.1111/cts.70064.
Mehta V, Karnam G, Madgula V
Mater Today Bio. 2024; 27:101143.
PMID: 39070097
PMC: 11279310.
DOI: 10.1016/j.mtbio.2024.101143.
Guengerich F
Pharmacol Rev. 2024; 76(6):1104-1132.
PMID: 39054072
PMC: 11549934.
DOI: 10.1124/pharmrev.124.001173.
Debad S, Allen D, Bandele O, Bishop C, Blaylock M, Brown P
ALTEX. 2024; 41(3):402-424.
PMID: 38898799
PMC: 11413798.
DOI: 10.14573/altex.2403261.
Prediction of the First-Pass Metabolism of a Drug After Oral Intake Based on Structural Parameters and Physicochemical Properties.
Hosseini M, Alizadeh A, Shayanfar A
Eur J Drug Metab Pharmacokinet. 2024; 49(4):449-465.
PMID: 38733548
DOI: 10.1007/s13318-024-00892-6.
Screening oral drugs for their interactions with the intestinal transportome via porcine tissue explants and machine learning.
Shi Y, Reker D, Byrne J, Kirtane A, Hess K, Wang Z
Nat Biomed Eng. 2024; 8(3):278-290.
PMID: 38378821
DOI: 10.1038/s41551-023-01128-9.
Evaluating the bioequivalence of levetiracetam brand and generic oral tablets available in the Saudi market in vivo.
ALRabeeah D, Almomen A, Alzoman N, Arafah M
Saudi Pharm J. 2023; 31(10):101758.
PMID: 37753207
PMC: 10518482.
DOI: 10.1016/j.jsps.2023.101758.
Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders.
Hornberger K, Araujo E
J Med Chem. 2023; 66(12):8281-8287.
PMID: 37279490
PMC: 10291545.
DOI: 10.1021/acs.jmedchem.3c00740.
Development of 3D-Bioprinted Colitis-Mimicking Model to Assess Epithelial Barrier Function Using Albumin Nano-Encapsulated Anti-Inflammatory Drugs.
Almutary A, Alnuqaydan A, Almatroodi S, Bakshi H, Chellappan D, Tambuwala M
Biomimetics (Basel). 2023; 8(1).
PMID: 36810372
PMC: 9944493.
DOI: 10.3390/biomimetics8010041.
Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist.
Zhao J, Wang S, Markison S, Kim S, Han S, Chen M
ACS Med Chem Lett. 2023; 14(1):66-74.
PMID: 36655128
PMC: 9841592.
DOI: 10.1021/acsmedchemlett.2c00431.
Sex Differences in Intestinal P-Glycoprotein Expression in Wistar versus Sprague Dawley Rats.
Madla C, Qin Y, Gavins F, Liu J, Dou L, Orlu M
Pharmaceutics. 2022; 14(5).
PMID: 35631615
PMC: 9143158.
DOI: 10.3390/pharmaceutics14051030.
Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series.
McAllister M, Flanagan T, Cole S, Abend A, Kotzagiorgis E, Limberg J
Pharmaceutics. 2022; 14(5).
PMID: 35631595
PMC: 9148161.
DOI: 10.3390/pharmaceutics14051010.
Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery.
Naga D, Parrott N, Ecker G, Olivares-Morales A
Mol Pharm. 2022; 19(7):2203-2216.
PMID: 35476457
PMC: 9257750.
DOI: 10.1021/acs.molpharmaceut.2c00040.
Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence.
Alshawwa S, Kassem A, Farid R, Mostafa S, Labib G
Pharmaceutics. 2022; 14(4).
PMID: 35456717
PMC: 9026217.
DOI: 10.3390/pharmaceutics14040883.
Prediction of Oral Drug Absorption in Rats from In Vitro Data.
Akiyama Y, Matsumura N, Ono A, Hayashi S, Funaki S, Tamura N
Pharm Res. 2022; 40(2):359-373.
PMID: 35169960
DOI: 10.1007/s11095-022-03173-6.
Recent Analytical Approaches for the Study of Bioavailability and Metabolism of Bioactive Phenolic Compounds.
Fernandez-Ochoa A, de la Luz Cadiz-Gurrea M, Fernandez-Moreno P, Rojas-Garcia A, Arraez-Roman D, Segura-Carretero A
Molecules. 2022; 27(3).
PMID: 35164041
PMC: 8838714.
DOI: 10.3390/molecules27030777.
Influence of methylxanthines isolated from Bancha green tea on the pharmacokinetics of sildenafil in rats.
Radeva-Llieva M, Stoeva S, Hvarchanova N, Zhelev I, Georgiev K
Daru. 2022; 30(1):75-84.
PMID: 35146639
PMC: 9114228.
DOI: 10.1007/s40199-022-00433-z.
Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312).
Pawaskar D, Chen X, Glassman F, May F, Roberts A, Biondo M
Clin Transl Sci. 2021; 15(3):709-720.
PMID: 34811931
PMC: 8932701.
DOI: 10.1111/cts.13192.
A White Paper on Collagen Hydrolyzates and Ultrahydrolyzates: Potential Supplements to Support Joint Health in Osteoarthritis?.
Mobasheri A, Mahmoudian A, Kalvaityte U, Uzieliene I, Larder C, Iskandar M
Curr Rheumatol Rep. 2021; 23(11):78.
PMID: 34716494
PMC: 8556166.
DOI: 10.1007/s11926-021-01042-6.